MOTRIN 200MG 200 MG
IBUPROFEN : 200 MG · DIN 02186934 · MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
Health Canada status: MARKETED
What is MOTRIN 200MG?
MOTRIN 200MG 200 MG contains IBUPROFEN : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02186934, held by MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Mar-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MOTRIN 200MG used for?
Relief of headache (migraine/tension), menstrual pain, toothache, inflammation (arthritis, strains/sprains), muscle/joint/backache, cold/flu symptoms, and reduction of fever.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02186934 |
|---|---|
| Brand name | MOTRIN 200MG |
| Generic / active ingredient | IBUPROFEN : 200 MG |
| Manufacturer | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | M01AE01 IBUPROFEN |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Mar-2026 |
| Original market date | 1972-12-31 00:00:00 |
How is it administered?
Adults: 200-400 mg every 4–6 hours as required. Do not exceed 1200 mg/24 hours. Use lowest effective dose for shortest duration. Take with food or milk if GI upset occurs.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (Section 11 mentioned in TOC but content not in snippet).
How is it supplied?
200 mg: Bottles of 24, 90, 150; 300 mg: Bottles of 60; 400 mg: Bottles of 16, 45.
Contraindications
Hypersensitivity to ibuprofen/NSAIDs/ASA; active peptic ulcer or GI bleeding; severe hepatic or renal impairment (CrCl <30 ml/min); hyperkalemia; SLE; 3rd trimester pregnancy; peri-operative heart surgery.
Warnings and precautions
Serious GI toxicity (bleeding/ulceration) can occur without warning. Increased risk of CV thrombotic events, MI, and stroke. Risk of renal toxicity in elderly/dehydrated patients.
What can be used instead?
Other Canadian products sharing ATC code M01AE01 IBUPROFEN. 46 of 143 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADVIL 12 HOUR | 600 MG | TABLET (EXTENDED-RELEASE) | HALEON CANADA ULC | MARKETED | DIN 02443562 |
| ADVIL ARTHRITIS PAIN | 400 MG | CAPSULE | HALEON CANADA ULC | MARKETED | DIN 02415623 |
| ADVIL CAPLETS | 200 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 01933531 |
| ADVIL EXTRA STRENGTH CAPLETS | 400 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 02244577 |
| ADVIL EXTRA STRENGTH LIQUI-GELS | 400 MG | CAPSULE | HALEON CANADA ULC | MARKETED | DIN 02248231 |
| ADVIL LIQUI-GELS | 200 MG | CAPSULE | HALEON CANADA ULC | MARKETED | DIN 02241769 |
| ADVIL MIGRAINE & HEADACHE | 400 MG | CAPSULE | HALEON CANADA ULC | MARKETED | DIN 02560380 |
| ADVIL MINI-GELS | 200 MG | CAPSULE | HALEON CANADA ULC | MARKETED | DIN 02485400 |
| ADVIL MUSCLE AND JOINT | 400 MG | TABLET | HALEON CANADA ULC | MARKETED | DIN 02355701 |
| ADVIL PEDIATRIC DROPS | 40 MG | DROPS | HALEON CANADA ULC | MARKETED | DIN 02242522 |
Who else supplies IBUPROFEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IBUPROFEN appears in 3753 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.